Aktiesnakken — Marts 2010
-
Dog opnåede de
patienter, der udelukkende blev behandlet med zalutumumab, en forbedring på 61%
i den progressionsfrie overlevelse sammenlignet med patienter, der udelukkende
blev behandlet med BSC (p=0,0010). -
71,25
-
72
-
vildt....
-
føler med jer, men det babelstårn er færdigt...
-
føler med jer drenge
-
(sagde manden der boede i glashuset bioporto)
-
damn kondolerer.
-
jeg var relativ tæt på at købe en stak gen aktier i fredags...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind